Earnings Scheduled For May 4, 2022
Companies Reporting Before The Bell
• Seres Therapeutics (NASDAQ:MCRB) is estimated to report quarterly loss at $0.52 per share on revenue of $8.48 million.
What 4 Analyst Ratings Have To Say About Global Blood Therapeutics
Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings within the last quarter:
Morgan Stanley Maintains Equal-Weight on Global Blood Therapeutics, Raises Price Target to $31
Morgan Stanley maintains Global Blood Therapeutics (NASDAQ:GBT) with a Equal-Weight and raises the price target from $28 to $31.
Oppenheimer Maintains Outperform on Global Blood Therapeutics, Lowers Price Target to $86
Oppenheimer analyst Mark Breidenbach maintains Global Blood Therapeutics (NASDAQ:GBT) with a Outperform and lowers the price target from $92 to $86.
Global Blood Therapeutics Q4 EPS $(1.36) Misses $(1.13) Estimate, Sales $56.10M Beat $55.44M Estimate
Global Blood Therapeutics (NASDAQ:GBT) reported quarterly losses of $(1.36) per share which missed the analyst consensus estimate of $(1.13) by 20.35 percent. This is a 36 percent decrease over losses of $(1.00) per
The Daily Biotech Pulse: Kodiak Sinks On Adverse Study Outcome, Marinus Flags Delay In Clinical Trial, Mainz Biomed Gains On Positive Regulatory Development
Here's a roundup of top developments in the biotech space over the last 24 hours.
Stocks In Focus
Kodiak's Wet AMD Treatment KSI-301 Did Not Meet Primary Endpoint In Phase 2b/3 Study
Earnings Scheduled For February 23, 2022
Companies Reporting Before The Bell
• Sapiens Intl Corp (NASDAQ:SPNS) is likely to report earnings for its fourth quarter.
The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News Flow
Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries.
Global Blood Therapeutics’ Oxbryta Scores European Approval For Sickle Cell Disease
The European Commission (EC) has approved Global Blood Therapeutics Inc's
The Daily Biotech Pulse: Avenue Tumbles On Negative Adcom Verdict, Moderna’s Expanded Deal With Rovi, Gilead Takes Equity Stake In Hookipa
Here's a roundup of top developments in the biotech space over the last 24 hours.